Latest Period
Q1 2026
Security Snapshot
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) Institutional Ownership
CUSIP: 29664W105
13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026
Institutions Reporting
204
Shares (Excl. Options)
174,381,745
Price
$2.74
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- ESPR on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 174,381,745
- Total 13F value
- $477,986,655
- Portfolio coverage rank
- 0%
- Share change
- +22,430,727
- Value change
- +$57,034,072
- Number of holders
- 204
- Shares outstanding
- 257,369,571
- SEC-reported price per share
- $3.13
- Insider filing price
- $3.13
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 29664W105.
- 204 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 201 to 204 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $559,772,067 to $477,986,655.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 204 institutions filings for Q1 2026.
Security key
29664W105
Latest holder period
Q1 2026
13F holders
204
13D/G owners
4
CIK / CUSIP context first
Open Q1 2026 holders
ESPR full holder history
Esperion Therapeutics, Inc. SEC filings
Esperion Therapeutics, Inc. company facts
Esperion Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 29664W105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
ESPR
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| GLAZER CAPITAL, LLC | 8.2% | $65,443,934 | 20,975,620 | Glazer Capital, LLC | 01 Jun 2026 | |||
| WASATCH ADVISORS LP | 6.1% | +65% | $43,206,778 | +$23,857,290 | 15,768,897 | +123% | Wasatch Advisors LP | 31 Mar 2026 |
| Two Seas Capital LP | 4.7% | -6% | $25,836,769 | -$543,915 | 9,749,724 | -2.1% | Two Seas Capital LP | 30 Sep 2025 |
| BB BIOTECH AG | 4.9% | -2% | $8,821,598 | -$227,500 | 9,694,064 | -2.5% | BB Biotech AG | 04 Mar 2025 |
As of 31 Mar 2026, 204 institutional investors reported holding 174,381,745 shares of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR). This represents 68% of the company’s total 257,369,571 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
57%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6.9% | 17,852,427 | +0.96% | 0% | $48,915,650 |
| WASATCH ADVISORS LP | 6.1% | 15,768,897 | +67% | 0.29% | $43,206,778 |
| Two Seas Capital LP | 4.4% | 11,394,833 | -4.3% | 1.4% | $31,221,842 |
| ORBIMED ADVISORS LLC | 4.1% | 10,570,300 | +77% | 0.65% | $28,962,622 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.1% | 10,433,760 | 0% | 0% | $28,588,502 |
| TWO SIGMA INVESTMENTS, LP | 3.7% | 9,458,779 | +99% | 0.02% | $25,917,054 |
| MARSHALL WACE, LLP | 2.7% | 7,075,083 | +29% | 0.02% | $19,385,727 |
| STATE STREET CORP | 2.7% | 7,055,794 | +19% | 0% | $19,332,876 |
| D. E. Shaw & Co., Inc. | 2.5% | 6,540,785 | -5.3% | 0.01% | $17,921,751 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3% | 5,955,739 | +3.8% | 0% | $16,322,581 |
| AIGH Capital Management LLC | 1.7% | 4,400,000 | +10% | 2.5% | $12,056,000 |
| UBS Group AG | 1.7% | 4,291,711 | +1270% | 0% | $11,759,289 |
| ARMISTICE CAPITAL, LLC | 1.5% | 3,930,125 | 0.36% | $10,768,543 | |
| PenderFund Capital Management Ltd. | 1.5% | 3,891,926 | -11% | 1.7% | $10,663,877 |
| Nuveen, LLC | 1.4% | 3,613,709 | +0.04% | 0% | $9,901,563 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.4% | 3,532,563 | 0% | 0% | $9,679,223 |
| Privium Fund Management B.V. | 1.3% | 3,299,441 | 1.9% | $9,040,468 | |
| MORGAN STANLEY | 1.1% | 2,735,644 | -22% | 0% | $7,495,664 |
| ROYCE & ASSOCIATES LP | 1% | 2,626,995 | -27% | 0.07% | $7,197,966 |
| GOLDMAN SACHS GROUP INC | 0.94% | 2,410,454 | -15% | 0% | $6,604,644 |
| JONES FINANCIAL COMPANIES LLLP | 0.83% | 2,135,741 | +2% | 0% | $5,851,930 |
| NORTHERN TRUST CORP | 0.82% | 2,104,008 | +5.4% | 0% | $5,764,982 |
| Voleon Capital Management LP | 0.74% | 1,916,698 | +66% | 0.11% | $5,251,753 |
| Eversept Partners, LP | 0.67% | 1,735,963 | -55% | 0.31% | $4,756,539 |
| Velan Capital Investment Management LP | 0.67% | 1,720,000 | +42% | 3% | $4,712,800 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
49
Latest
Q1 2026
Rows shown
1-25 of 49
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 174,381,745 | $477,986,655 | +$57,034,072 | $2.74 | 204 |
| 2025 Q4 | 151,305,588 | $559,772,067 | +$165,257,335 | $3.70 | 201 |
| 2025 Q3 | 107,960,329 | $286,090,424 | +$31,947,033 | $2.65 | 187 |
| 2025 Q2 | 98,221,986 | $96,659,560 | -$21,194,525 | $0.98 | 161 |
| 2025 Q1 | 111,244,473 | $160,207,390 | -$24,300,645 | $1.44 | 183 |
| 2024 Q4 | 126,046,299 | $277,285,420 | +$4,393,183 | $2.20 | 188 |
| 2024 Q3 | 128,986,677 | $212,839,069 | -$18,982,245 | $1.65 | 181 |
| 2024 Q2 | 136,753,565 | $303,582,298 | +$17,706,459 | $2.22 | 173 |
| 2024 Q1 | 125,253,343 | $335,669,495 | +$141,351,114 | $2.68 | 147 |
| 2023 Q4 | 71,634,221 | $214,185,830 | -$13,154,422 | $2.99 | 127 |
| 2023 Q3 | 77,232,361 | $75,678,982 | -$1,733,880 | $0.98 | 120 |
| 2023 Q2 | 74,286,796 | $103,280,736 | -$10,483,186 | $1.39 | 121 |
| 2023 Q1 | 80,929,285 | $128,750,548 | -$22,081,506 | $1.59 | 161 |
| 2022 Q4 | 73,478,005 | $457,748,937 | +$39,215,603 | $6.23 | 164 |
| 2022 Q3 | 62,444,882 | $418,381,560 | +$53,328,619 | $6.70 | 143 |
| 2022 Q2 | 55,366,705 | $352,132,262 | +$24,287,037 | $6.36 | 128 |
| 2022 Q1 | 51,922,058 | $241,219,302 | -$10,656,706 | $4.64 | 121 |
| 2021 Q4 | 53,613,124 | $268,022,905 | +$97,310,967 | $5.00 | 119 |
| 2021 Q3 | 24,797,305 | $298,815,522 | -$61,530,602 | $12.05 | 133 |
| 2021 Q2 | 28,340,478 | $599,385,890 | -$18,947,335 | $21.15 | 140 |
| 2021 Q1 | 28,702,213 | $805,059,737 | -$64,474,348 | $28.05 | 151 |
| 2020 Q4 | 30,878,165 | $802,895,778 | -$34,208,444 | $26.00 | 152 |
| 2020 Q3 | 31,640,175 | $1,176,015,102 | -$28,756,691 | $37.17 | 165 |
| 2020 Q2 | 31,971,491 | $1,640,380,010 | +$123,898,647 | $51.31 | 179 |
| 2020 Q1 | 29,570,957 | $916,082,618 | +$53,953,340 | $31.53 | 157 |